Arsenal Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.arsenalbio.com
AB-2100, an Integrated Circuit T (ICT) Cell Therapy in Patients with Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Phase 1
Recruiting
- Conditions
- Advanced/Metastatic Clear Cell Renal Cell CarcinomaRecurrence
- Interventions
- Biological: AB-2100
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Arsenal Biosciences, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT06245915
- Locations
- 🇺🇸
Dana Farber Cancer Institue, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York City, New York, United States
🇺🇸Huntsman Cancer Institute - Univ of Utah Health, Salt Lake City, Utah, United States
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Phase 1
Active, not recruiting
- Conditions
- Ovarian NeoplasmsFallopian Tube NeoplasmsAbdominal NeoplasmRecurrencePeritoneal NeoplasmsNeoplasms, Glandular and EpithelialOvarian DiseasesCarcinoma, Ovarian EpithelialGenital Neoplasm, Female
- Interventions
- Biological: AB-1015
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Arsenal Biosciences, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT05617755
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸U of Colorado Cancer Center - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸U of Iowa Health Care, Iowa City, Iowa, United States
© Copyright 2025. All Rights Reserved by MedPath